Provention Bio (NASDAQ:PRVB) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Provention Bio (NASDAQ:PRVB) issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.11), Fidelity Earnings reports.

NASDAQ PRVB opened at $4.39 on Friday. The stock has a market capitalization of $168.13 million and a P/E ratio of -3.69. Provention Bio has a 12 month low of $1.52 and a 12 month high of $8.00.

A number of analysts have recently issued reports on PRVB shares. Leerink Swann started coverage on Provention Bio in a research report on Friday, February 22nd. They set an “outperform” rating on the stock. Svb Leerink initiated coverage on Provention Bio in a research report on Friday, February 22nd. They set an “outperform” rating and a $6.00 target price for the company. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Provention Bio in a research report on Thursday, April 25th. Finally, Zacks Investment Research upgraded Provention Bio from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Saturday, March 23rd.

TRADEMARK VIOLATION NOTICE: “Provention Bio (NASDAQ:PRVB) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS” was first published by Rockland Register and is owned by of Rockland Register. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://rocklandregister.com/2019/06/01/provention-bio-prvb-releases-quarterly-earnings-results-misses-estimates-by-0-11-eps.html.

Provention Bio Company Profile

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

See Also: Consumer behavior in bull markets

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.